Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Texto completo Resumo
Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
Artigos de referência
1. Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999 Apr 29;340(17):1330-40. Resumo
2. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. Resumo
3. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.Texto completo Resumo
4. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789-99.Texto completo Resumo
5. Hasford J, Pfirrmann M, Hehlmann R, et al; Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8.Texto completo Resumo
6. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016 Jan;30(1):48-56. Resumo
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
8. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
9. Zhang XS, Gale RP, Huang XJ, et al. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022 Feb;36(2):482-491.Texto completo Resumo
10. Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020 Aug;34(8):2138-49.Texto completo Resumo
11. Goldman J. ABC of clinical haematology: chronic myeloid leukaemia. BMJ. 1997 Mar 1;314(7081):657-60. [Erratum in: BMJ 1997 Mar 15;314(7083):812.]Texto completo Resumo
12. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.Texto completo Resumo
13. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2023 [internet publication].Texto completo
14. Cancer Research UK. Chronic myeloid leukaemia (CML) incidence statistics [internet publication].Texto completo
15. Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101(6):362-8.Texto completo Resumo
16. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012 Mar;95(3):232-8. Resumo
17. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15;341(3):164-72. Resumo
18. American Cancer Society. Risk factors for chronic myeloid leukemia. Feb 2024 [internet publication].Texto completo
19. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009 Jan;11(1):4-11.Texto completo Resumo
20. Adnan-Awad S, Kim D, Hohtari H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2021 Jul;35(7):1964-75.Texto completo Resumo
21. Adnan-Awad S, Hohtari H, Javarappa KK, et al. BCR-ABL1 p190 in CML: a minor breakpoint with a major impact. Blood. 2019 Nov;134(1 suppl):190.Texto completo
22. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009 Jan;89(1):14-23. Resumo
23. Kuan JW, Melaine Michael S. The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Med J Malaysia. 2018 Apr;73(2):78-85.Texto completo Resumo
24. Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012 Apr;17 Suppl 1:S72-4.Texto completo Resumo
25. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013 Jun;37(3):247-54. Resumo
26. Ural AU, Beyzadeoglu M, Avcu F, et al. Chronic myeloid leukemia following radiotherapy for carcinoma of the cervix: report of a case and brief review of the literature. Am J Hematol. 2007 May;82(5):415-6.Texto completo Resumo
27. Miyoshi I, Mori M, Yamasaki I, et al. Is there an entity of radiation-induced chronic myeloid leukemia? Report of a case and brief review of the literature. J Clin Exp Hematop. 2020;60(1):24-5.Texto completo Resumo
28. Leuraud K, Richardson DB, Cardis E, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015 Jul;2(7):e276-81.Texto completo Resumo
29. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 Mar;93(3):442-59.Texto completo Resumo
30. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br J Haematol. 1997 Jan;96(1):111-6. Resumo
31. Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology. 2020 Dec;25(1):181-5.Texto completo Resumo
32. Sevastos N, Theodossiades G, Efstathiou S, et al. Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med. 2006 Mar;147(3):139-44. Resumo
33. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Texto completo Resumo
34. Cross NC, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts of chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993 Sep 15;82(6):1929-36.Texto completo Resumo
35. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.Texto completo Resumo
36. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemias. Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol. 1994 Aug;87(4):746-54. Resumo
37. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7.Texto completo Resumo
38. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1;82(3):691-703.Texto completo Resumo
39. Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022 Jul;36(7):1701-2.Texto completo Resumo
40. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Texto completo Resumo
41. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Texto completo Resumo
42. Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016 Aug 20;34(24):2851-7.Texto completo Resumo
43. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May;2(5):e186-93.Texto completo Resumo
44. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15;101(10):3794-800.Texto completo Resumo
45. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15;117(6):1113-22.Texto completo Resumo
46. Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021 May;35(5):1344-55.Texto completo Resumo
47. Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
48. O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004.Texto completo Resumo
49. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar 9;376(10):917-27.Texto completo Resumo
50. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123-32. Resumo
51. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51.Texto completo Resumo
52. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12.Texto completo Resumo
53. Talpaz M, Shah N, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41.Texto completo Resumo
54. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-76.Texto completo Resumo
55. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9.Texto completo Resumo
56. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. Resumo
57. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly fiagnosed vhronic myeloid leukemia: results From the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231-7.Texto completo Resumo
58. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016 Jul 10;34(20):2333-40.Texto completo Resumo
59. Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 Jul;36(7):1825-33.Texto completo Resumo
60. Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 Feb;35(2):440-53.Texto completo Resumo
61. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009 Dec 24;114(27):5426-35.Texto completo Resumo
62. Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol. 2020;143(3):217-31.Texto completo Resumo
63. Müller MC, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017 Dec;120:52-9.Texto completo Resumo
64. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019 Dec 12;381(24):2315-26.Texto completo Resumo
65. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-41.Texto completo Resumo
66. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96.Texto completo Resumo
67. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].Texto completo
68. Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021 Nov 25;138(21):2042-50.Texto completo Resumo
69. Pulte ED, Chen H, Price LSL, et al. FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial. Oncologist. 2022 Mar 4;27(2):149-57.Texto completo Resumo
70. Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 Mar;37(3):617-26.Texto completo Resumo
71. Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022 Jun 16;139(24):3474-9.Texto completo Resumo
72. Cortes J, Lipton JH, Rea D, et al; Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27;120(13):2573-80.Texto completo Resumo
73. Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May;88(5):350-4.Texto completo Resumo
74. Cortes JE, Kantarjian HM, Rea D, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up. Cancer. 2015 May 15;121(10):1637-44.Texto completo Resumo
75. Alvandi F, Kwitkowski VE, Ko CW, et al. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2014 Jan;19(1):94-9.Texto completo Resumo
76. Winer ES, DeAngelo DJ. A review of omacetaxine: a chronic myeloid leukemia treatment resurrected. Oncol Ther. 2018 Jun;6(1):9-20.Texto completo Resumo
77. Saifullah HH, Lucas CM. Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors? Cancers (Basel). 2021 Aug 19;13(16):4175.Texto completo Resumo
78. Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020 Aug;17(8):493-503. Resumo
79. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018 Jun;19(6):747-57. Resumo
80. Niederwieser C, Kröger N. Transplantation in CML in the TKI era: who, when, and how? Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):114-22.Texto completo Resumo
81. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Texto completo
82. Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019 Nov;54(11):1764-74. Resumo
83. Shimada H, Tanizawa A, Kondo T, et al. Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era. Transplant Cell Ther. 2022 Jul;28(7):376-89.Texto completo Resumo
84. Niederwieser C, Morozova E, Zubarovskaya L, et al. Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. Bone Marrow Transplant. 2021 Nov;56(11):2834-41.Texto completo Resumo
85. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9.Texto completo Resumo
86. Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011 Jun;35(6):777-82. Resumo
87. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022 Feb;9(2):e121-32.Texto completo Resumo
88. Copland M. Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. Br J Haematol. 2022 Dec;199(5):665-78.Texto completo Resumo
89. Abaza Y, Kantarjian H, Alwash Y, et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 Nov;95(11):1288-95.Texto completo Resumo
90. Ruggiu M, Oberkampf F, Ghez D, et al. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leuk Lymphoma. 2018 Jul;59(7):1659-65. Resumo
91. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 1;120(3):373-80.Texto completo Resumo
92. ClinicalTrials.gov. TKI and interferon alpha evaluation initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER). NCT01657604. May 2023 [internet publication].Texto completo
93. Hochhaus A, Burchert A, Saußele S, et al. S157: nilotinib vs. nilotinib + peg-interferon αlpha induction and nilotinib or peg-interferon αlpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients - the TIGER trial. Hemasphere. 2023 Aug;7(Suppl):e4695659.Texto completo
94. ClinicalTrials.gov. A pivotal study of HQP1351 in patients of chronic myeloid leukemia in accelerated phase with T315I mutation. NCT03883100. Apr 2023 [internet publication].Texto completo
95. ClinicalTrials.gov. A pivotal study of HQP1351 in patients of chronic myeloid leukemia in chronic phase with T315I mutation. NCT03883087. Apr 2023 [internet publication].Texto completo
96. ClinicalTrials.gov. A pivotal study of HQP1351 in patients with chronic myeloid leukemia in chronic phase. NCT04126681. Apr 2023 [internet publication].Texto completo
97. Kantarjian H, Sawyers C, Hochhaus A, et al; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645-52. [Erratum in: N Engl J Med. 2002 Jun 13;346(24):1923.]Texto completo Resumo
98. Hughes TP, Hochhaus A, Branford S, et al; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11;116(19):3758-65.Texto completo Resumo
99. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014 Jul 24;124(4):511-8.Texto completo Resumo
100. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017 Nov 15;123(22):4391-402.Texto completo Resumo
101. Fachi MM, Tonin FS, Leonart LP, et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019 Oct;85(10):2280-91.Texto completo Resumo
102. Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):78-82.Texto completo Resumo
103. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010 Jul;16(4):351-6. Resumo
104. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015 Dec 10;33(35):4210-8. Resumo
105. Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26;3(6):851-61.Texto completo Resumo
106. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 Feb;84(2):161-9.Texto completo Resumo
107. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009 Nov;23(11):1957-63. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal